Jazz Pharmaceuticals’ Sunosi (solriamfetol) Receives EMA’s MAA for Excessive Daytime Sleepiness in Adults with Narcolepsy or Obstructive Sleep Apnea

 Jazz Pharmaceuticals’ Sunosi (solriamfetol) Receives EMA’s MAA for Excessive Daytime Sleepiness in Adults with Narcolepsy or Obstructive Sleep Apnea

Jazz Pharmaceuticals’ Sunosi (solriamfetol) Receives EMA’s MAA for Excessive Daytime Sleepiness in Adults with Narcolepsy or Obstructive Sleep Apnea

Shots:

  • The MAA is based on four studies included in TONES program assessing Sunosi (75mg/150mg or 37.5mg, 75mg and 150 mg) vs PBO in 900+ adults with EDS associated with narcolepsy or OSA respectively
  • TONES 2 & 3 studies result: @12wks. improvement in their overall clinical condition as assessed by PGIc scale (68-74% @75mg & 78-90% @150mg) respectively; improvement in wakefulness
  • Sunosi is a dual-acting dopamine and norepinephrine reuptake inhibitor and has received the US FDA’s approval on Mar 20, 2019 to improve wakefulness, designated as Schedule IV medicine by the US Drug Enforcement Agency on Jun 17, 2019

Click here to­ read full press release/ article | Ref: PRNewswire | Image: Kbm-hogue

Tuba Khan

Tuba Khan is an Editor and Digital Marketing expert at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in Lifesciences industry. She covers Pharma, Medical devices, Diagnostics and Digital health segment. Tuba also has an experience of digital and social media marketing and can run the campaign independently. She is also certified as a Digital marketer and social media marketer. She can be contacted on tuba@pharmashots.com

Related post